In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies” Dr. Robert W. Chen argues that there is value to using brentuximab vedotin as consolidation therapy shorlty following auto-SCT in Hodgkin Lymphoma.
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP
© 2015 Imedex, LLC.
Advertisement